Struthers Richard Scott
President & CEO
Struthers Richard Scott has filed 7 SEC Form 4 filings (36 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, Struthers Richard Scott is listed as President & CEO at Crinetics Pharmaceuticals, Inc. Inside the rolling window, Struthers Richard Scott reported no open-market purchases and 1 open-market sale totaling $822K in CRNX.
Companies traded
Other insiders at CRNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$822K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 26, 2025 | CRNX | Sale | $180K |
Frequently asked questions
How many SEC Form 4 filings has Struthers Richard Scott made?
Struthers Richard Scott has filed 7 SEC Form 4 filings (36 transaction rows) across 1 company since 2025.
Which companies does Struthers Richard Scott trade?
Struthers Richard Scott has filed SEC Form 4 disclosures for 1 company, including CRNX.
When was Struthers Richard Scott's most recent SEC Form 4 filing?
Struthers Richard Scott's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is Struthers Richard Scott's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Struthers Richard Scott is listed as President & CEO.
What is Struthers Richard Scott's total buy and sell value in the current window?
Inside the rolling retention window, Struthers Richard Scott bought $0 and sold $822K based on SEC Form 4 filings.
What was Struthers Richard Scott's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 21,981 CRNX shares on 2026-03-16, worth $822K, per SEC Form 4 filings.